Payer demand for genetic tests shakes up pharma's selling practices
This article was originally published in Scrip
Executive Summary
As pharmacy benefit managers and insurers begin not only paying for pre-prescription genotyping but actively promoting it, personalised medicine in the US may get a shot in the arm. Daniel B Moskowitz discusses how that could change the way pharma picks drugs for development and markets them once they are approved.